Suppression of tumor cell growth both in nude mice and in culture by n-3 polyunsaturated fatty acids: Mediation through cyclooxygenase-independent pathways

Cancer Research

Volumn 61, Issue 4, 2001, Pages 1386-1391

  Boudreau, Mary D ^a   Sohn, Kyung Hee ^a   Rhee, Sang Hoon ^a   Lee, Sam W ^c   Hunt, Jay D ^b   Hwang, Daniel H ^a  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; FISH OIL; LINOLEIC ACID; OMEGA 3 FATTY ACID; PROSTAGLANDIN SYNTHASE; RETROVIRUS VECTOR; SAFFLOWER OIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; COLON TUMOR; CONTROLLED STUDY; DIETARY INTAKE; DRUG MECHANISM; ENZYME INHIBITION; FEMALE; GENETIC TRANSFECTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; CELL ADHESION; CELL DIVISION; COLONIC NEOPLASMS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DIET; DNA, COMPLEMENTARY; FATTY ACIDS, OMEGA-3; FATTY ACIDS, UNSATURATED; FEMALE; GROWTH INHIBITORS; HUMANS; ISOENZYMES; LINOLEIC ACID; MEMBRANE PROTEINS; MICE; MICE, NUDE; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SAFFLOWER OIL; TRANSFECTION; TRIGLYCERIDES;

EID: 0035866384     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (86)

1. Fish oil and colon cancer
2. Cancer mortality among Alaskan natives
3. Breast cancer in Greenland-selected epidemiological, clinical, and histological features
4. Can nutrition explain the pattern of international epidemiology of hormone-dependent cancers?
5. The role of fat, fatty acids, and total energy intake in the etiology of human colon cancer
6. Relation of meat, fat, and fiber intake to the risk of colon cancer in a prospective study among women
7. Sugar, meat, and fat intake and non-dietary risk factors for colon cancer incidence in Iowa women (United States)
8. Fish n-3 fatty acids and human colorectal and breast cancer mortality
9. Dietary lipids and colon cancer
10. Effects of different doses of fish oil on rectal cell proliferation in patients with sporadic colon adenomas
11. Effect of ω-3 fatty acids on rectal mucosal cell proliferation in subjects at risk for colon cancer
12. Dietary fats and colon cancer: Animal model studies
13. Effect of dietary fish oil on azoxymethane-induced colon carcinogenesis in male F344 rats
14. Effect of different levels of ω-3 and ω-6 fatty acids on azoxymethane-induced colon carcinogenesis in F344 rats
15. Effect of diets high in ω-3 and ω-6 fatty acids on initiation and post-initiation stages of colon carcinogenesis
16. A fish oil diet inhibits colon cancer in mice
17. The effect of dietary ω-3 fatty acids (fish oil) on azoxymethanol-induced focal areas of dysplasia and colon tumor incidence
18. Effect of ω-3 fatty acids on growth of a rat mammary tumor
19. Dietary fish oil suppresses human colon tumor growth in athymic mice
20. Inhibitory effects of n-3 polyunsaturated fatty acids on sigmoid colon cancer transformants
21. Dietary fat, fatty acids, and prostate cancer
22. Effects of dietary ω-3 fatty acids on human breast cancer growth and metastases in nude mice
23. Effects of fatty acids and eicosanoid synthesis inhibitors on the growth of two human prostate cancer cell lines
24. Effects of dietary N-3 and saturated fats on growth rates of the human colonic cancer cell lines SW-620 and LS 174T in vivo in relation to tissue and plasma lipids
25. Quantitative effects of dietary polyunsaturated fats on the composition of fatty acids in rat tissues
26. Maintenance of lower proportions of (n-6) eicosanoid precursors in phospholipids of human plasma in response to added dietary (n-3) fatty acids
27. The effect of dose level of essential fatty acids upon fatty acid composition of the liver
28. A hypothesis involving competitive inhibitions in the metabolism of polyunsaturated fatty acids
29. Breast cancer, its recurrence, and patient survival in relation to tumor prostaglandins
30. Prostaglandins and breast cancer
31. Breastcancer osteolysis, bone metastases, and anti-osteolytic effect of aspirin
32. Prostaglandins in tumor-associated cells
33. Arachidonic acid transformation and tumor production
34. Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence
35. Isolation and characterization of the complementary DNA for sheep seminal vesicle prostaglandin endoperoxide synthase (cyclooxygenase)
36. Primary structure of sheep prostaglandin endoperoxide synthase deduced from cDNA sequence
37. The aspirin and heme-binding sites of ovine and murine prostaglandin endoperoxide synthases
38. Cloning of human gene encoding prostaglandin endoperoxide synthase and primary structure of the enzyme
39. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue
40. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing
41. A serum- and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein
42. Human cyclooxygenase-2 cDNA
43. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines
44. Cloning two isoforms of rat cyclooxygenase: Differential regulation of their expression
45. Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: Evidence for a transcriptional effect
46. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas
47. Expression of cyclooxygenase-1 and -2 in human colorectal cancer
48. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer
49. Aspirin use and reduced risk of fetal colon cancer
50. Aspirin and the risk of colorectal cancer in women
51. Aspirin use and lung, colon, and breast cancer incidence in a prospective study
52. Aspirin use and risk of fatal cancer
53. Colorectal cancer risk, chronic illnesses, operations, and medications: Case control results from the Melbourne Colorectal Cancer Study
54. A hypothesis: Nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer
55. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer
56. Nonsteroidal anti-inflammatory drugs and colorectal cancer
57. Aspirin use, cancer, and polyps of the large bowel
58. Differentiation of the immortalized adult neuronal progenitor cell line HC2S2 into neurons by regulatable suppression of the v-myc oncogene
59. Production of high-titer helper-free retroviruses by transient transfection
60. Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide
61. Radicicol, a protein tyrosine kinase inhibitor, suppresses the expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide and in experimental glomerulonephritis
62. Lack of dose response by dietary n-3 fatty acids at a constant ratio of n-3 to n-6 fatty acids in suppressing eicosanoid biosynthesis from arachidonic acid
63. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2
64. Identification of c-MYC as a target of the APC pathway
65. Δ716knockout mice by inhibition of cyclooxygenase 2 (COX-2)
66. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2
67. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential
68. Expression of COX-1 and COX-2 and gastrointestinal diseases
69. Overexpression of cyclooxygenase-2 induces cell cycle arrest
70. Sulindac causes rapid regression of preexisting tumors in Min/+ mice independent of prostaglandin biosynthesis
71. Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other nonsteroidal anti-inflammatory drugs
72. Peroxisome proliferators enhance cyclooxygenase-2 expression in epithelial cells
73. Differentiation and reversal of malignant changes in colon cancer through PPARγ
74. Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Δ 2, 14-prostaglandin J2
75. Activation of proliferator-activated receptors α and γ induces apoptosis of human monocyte-derived macrophages
76. Nonsteroidal anti-inflammatory drugs cause apoptosis and induce cyclooxygenases in chicken embryo fibroblasts
77. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells
78. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis
79. Two opposing effects of nonsteroidal anti-inflammatory drugs on the expression of the inducible cyclooxygenase-mediation through different signaling pathways
80. Molecular recognition of fatty acids by peroxisome proliferatoractivated receptors
81. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ
82. Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid reporter
83. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ
84. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay
85. Differential activation of peroxisome proliferatoractivated receptors by eicosanoids